PROGNOSTIC VALUE OF THE UFGSI SCORE FOR SEVERE CLINICAL PROGRESSION IN PATIENTS WITH FOURNIER’S GANGRENE AT BINH DAN HOSPITAL

Bá Tiến Dũng Mai1,2, , Quang Bình Đinh1, Minh Đạt Võ1
1 Khoa Nam học, Bệnh viện Bình Dân
2 Trường Đại học Y khoa Phạm Ngọc Thạch

Main Article Content

Abstract

Objective: To describe clinical and laboratory characteristics, treatment outcomes, and assess the discriminative value of the Uludag Fournier’s Gangrene Severity Index (UFGSI) for severe clinical progression in patients with Fournier’s gangrene at Binh Dan Hospital.


Subjects and methods: A retrospective descriptive study with analytic components was conducted in 50 patients with Fournier’s gangrene treated at the Department of Andrology, Binh Dan Hospital, from January 2021 to March 2025. Severe progression was defined as at least one of the following in-hospital events: sepsis, septic shock, or death. Discrimination of UFGSI was assessed using receiver operating characteristic analysis.


Results: The mean age was 52.7 ± 15.0 years. Diabetes mellitus and obesity were each present in 52.0%. Skin and soft-tissue infection of the perineal-genital region was the most frequent source (46.0%). All patients underwent surgery within 24 hours of admission, and debridement was performed in 76.0%. Septic shock occurred in 8 patients (16.0%), sepsis in 4 (8.0%), and death in 2 (4.0%). UFGSI showed good discrimination for severe progression (AUC = 0.86; 95% CI: 0.74-0.98; p < 0.001). Patients with UFGSI >9 had higher rates of septic shock and sepsis than those with UFGSI ≤9; both deaths occurred in the UFGSI >9 group.


Conclusion: UFGSI demonstrated good discrimination for severe progression in this cohort and may support early risk stratification. Its results should be interpreted alongside clinical assessment and validated in larger studies.

Article Details

References

1. Zhang KF, Shi CX, Chen SY, Wei W. (2022). Progress in multidisciplinary treatment of Fournier’s gangrene. Infect Drug Resist, 15:6869-6880.
2. Huayllani MT, Cheema AS, McGuire MJ, Janis JE. (2022). Practical review of the current management of Fournier’s gangrene. Plast Reconstr Surg Glob Open, 10(3):e4191.
3. El-Qushayri AE, Khalaf KM, Dahy A, et al. (2020). Fournier’s gangrene mortality: a 17-year systematic review and meta-analysis. Int J Infect Dis, 92:218-225.
4. Tufano A, Dipinto P, Passaro F, et al. (2023). The value of Fournier’s gangrene scoring systems on admission to predict mortality: a systematic review and meta-analysis. J Pers Med, 13(9):1283.
5. Yılmazlar T, Işık Ö, Öztürk E, Özer A, Gülcü B, Ercan I. (2014). Fournier’s gangrene: review of 120 patients and predictors of mortality. Ulus Travma Acil Cerrahi Derg, 20(5):333-337.
6. Hauser N, Huang C, Vaidya G, et al. (2024). Fournier’s Gangrene Severity Index and Charlson Comorbidity Index predict mortality, intensive care unit admission, and length of hospital stay in patients with Fournier’s gangrene: an analysis of 264 consecutive patients. Cureus, 16(12):e75281.
7. Truong MH, Ngo T, Nguyen QT, Le H. (2025). Diagnosis and treatment outcomes of Fournier’s gangrene at a tertiary hospital. Cureus, 17(4):e82344.
8. Vanguardia MKR, Lew C, Prabhakaran S, Kong JCH. (2024). Fournier’s gangrene: 15-year retrospective study at a tertiary hospital. BJS Open, 8(2):zrae022.